When a country is poised to introduce a new biomedical prevention product, policymakers want to ensure that their rollout plan is based on the latest science and provides clear, standardized procedures for implementation. The WHO publishes global guidance on delivering new HIV prevention products, but those recommendations need to be adapted to the local context.
Continue Reading
Three MTN studies – REACH, DELIVER, and B-PROTECTED – recently published critical new data on PrEP ring use among adolescent girls and young women (AGYW), pregnant individuals, and breastfeeding individuals in Africa. All studies offer compelling evidence that the ring is safe for use among these populations.
Continue Reading
Through oral PrEP, condoms, voluntary medical male circumcision, and antiretroviral treatment, USAID has helped to expand prevention options and access for all. Today, USAID continues to provide global leadership in the HIV response by expanding access to options with a new generation of HIV prevention products.
Continue Reading
What sets CATALYST apart is the study’s emphasis on meaningful involvement of young people at every stage of the research to understand end-user perspectives and help tailor the study to meet their needs. This makes us hopeful because the inclusion of young people in the CATALYST journey has not been tokenistic; rather our contributions have been reflected in the whole process so far. In this post, we describe three ways youth have been engaged in CATALYST.
Continue Reading
As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings.
Continue Reading
CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.
Continue Reading
New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.
Continue Reading
The success of efforts to introduce new pre-exposure prophylaxis (PrEP) methods for HIV prevention, such as the PrEP ring and injectable CAB PrEP, will also rely on local partners. That’s why one of MOSAIC’s five strategic objectives is dedicated to strengthening local partner capacity to design and implement high-quality product introduction activities and research.
Continue Reading
For the MOSAIC project team, the AIDS 2022 conference set the stage for embracing the introduction of new biomedical HIV prevention products and generating evidence on how to support choice and effective use. We attended the conference virtually and took away three key messages that resonate with our work on MOSAIC.
Continue Reading
The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.
Continue Reading